Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study-Reference-Cited by-同舟云学术

Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study

Published:2021-10-26 Issue:23 Volume:12 Page:3263-3272
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Wang Chin‐Chou¹²³^ORCID,Lai Chien‐Hao¹,Chang Yu‐Ping¹,Chang Huang‐Chih¹,Tseng Chia‐Cheng¹,Huang Kuo‐Tung¹,Lin Meng‐Chih¹²

Affiliation:

1. Divisions of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital Chang Gung University College of Medicine Kaohsiung Taiwan

2. Department of Respiratory Therapy, Kaohsiung Chang Gung Memorial Hospital Chang Gung University College of Medicine Kaohsiung Taiwan

3. Department of Respiratory Care Chang Gung University of Science and Technology Chiayi Taiwan

Funder

Chang Gung Medical Foundation

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14198

Reference44 articles.

1. First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?

2. Beyond ALK‐RET, ROS1 and other oncogene fusions in lung cancer;Kohno T;Transl Lung Cancer Res,2015

3. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

4. The biology and management of non-small cell lung cancer

5. Refining the treatment of NSCLC according to histological and molecular subtypes

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan;Targeted Oncology;2023-02-20